Trading Review for CEL-SCI Corp. Issued by InvestorSoup.com

• Press Release
• Source: InvestorSoup
• On 6:50 am EDT, Tuesday October 20, 2009

DALLAS, Oct. 20, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring CEL-SCI Corp. (AMEX:CVM - News). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

Related Quotes

Symbol	Price	Change
CVM	1.21	-0.04

{"s" : "cvm,genz,gild,life","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The investment report on CEL-SCI Corp. (AMEX:CVM - News) should be of particular interest to other biopharmaceutical companies: Gilead Sciences Inc. (Nasdaq:GILD - News), Genzyme Corp. (Nasdaq:GENZ - News) and Life Technologies Corp. (Nasdaq:LIFE - News).

It is available at: http://www.investorsoup.com/lp/CVM

Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup

CEL-SCI Corp. (CVM) is engaged in the development of a product called Multikine for the treatment of cancer. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted; it is the cancer immunotherapy that kills cancer cells in a targeted fashion and activates the general immune system to destroy the cancer. Multikine is a type of immunotherapy in that it is a comprehensive immunotherapy, incorporating both active and passive immune activity. The Company also develops CEL-1000, which is derived from a pre-clinical technology called Ligand Epitope Antigen Presentation System for protection for animals against avian flu, herpes, malaria and more.

In the report, the analyst notes:

"The Company has two partners who have agreed to participate in and pay for part of the phase III clinical trial for Multikine. However in light of the current capital market environment, the Company believes it is prudent not to start the phase III clinical trial until it has firm commitments in the form of partnerships and/or money raised for a substantial amount of cash to support the phase III clinical trial. Additionally, the Company obtained new financing of $5,845,241 in June of 2009, net of financing costs of $339,329. The Company is currently working toward a transaction that will finance its phase III clinical trial of Multikine.

"CVM is currently moving forward as fast as is possible with its proposed dendritic H1N1 treatment for hospitalized H1N1 patients, while proceeding with due caution and taking all necessary steps to meet regulatory requirements."

To read the entire report visit: http://www.investorsoup.com/lp/CVM

See what investors say about these stocks at: http://www.stockhideout.com/

InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com .

InvestorSoup.com Disclosure

InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.

InvestorSoup.com
Jeffrey Brown, Editor
(469)-252-3505
info@investorsoup.com